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Summary 
Extracellular  adenosine triphosphate (eATP) has been suggested to play a role in lymphocyte- 
induced tumor destruction. We now provide evidence that a protein responsible for ATP synthesis 
in mitochondria may also play a physiologic role in major histocompatibility complex-independent, 
lymphocyte-mediated  cytotoxicity. A 51.5-kD protein (p51.5) beating structural and immunologic 
characteristics  of the B subunit of H + transporting ATP synthase (E.C. 3.6.1.34,  B-H +ATPase, 
published molecular mass of 51.6 kD) was detected on the plasma membrane of three different 
human tumor cell lines studied. NH2-terminal amino acid sequence analysis of purified p51.5 
from K562 tumor cells revealed 100% homology of 16 residues identified in the first 21 positions 
to the known sequence of human mitochondrial B-H § ATPase. Antibody directed against a 2l- 
iner peptide in the ATP binding region of B-H+ATPase  (anti-B)  reacted with only one band 
on Western blots of whole tumor extracts  and tumor membrane extracts  suggesting that the 
antiserum reacts with a single species of protein. Anti-B reacted with the cell membranes of 
tumor ceils as determined by fluorescence-activated  flow cytometry and immunoprecipitated a 
51.5-kD protein from surface-labeled  neoplastic cells (but not human erythrocytes and lymphocytes). 
Purified p51.5 bound to human lymphocytes and inhibited natural killer (NK) cell-mediated 
cytotoxicity. Furthermore, anti-B  treatment of the K562 and A549 tumor cell lines inhibited 
NK (by >95%) and interleukin 2-activated killer (LAK) cell (by 75%) cytotoxicity, respectively. 
Soluble p51.5 upon binding to lymphocytes retained its reactivity to anti-B suggesting that the 
ATP binding domain and the lymphocyte-receptor binding domain reside in distinct regions 
of the ligand.  These results suggest that B-H +ATPase or  a nearly identical molecule is an 
important ligand in the effector phase (rather than the recognition phase) of a cytolytic pathway 
used by naive NK and LAK cells. 
L 
mphocytes that directly destroy target cells upon contact 
(cytolytic lymphocytes) play an important protective role 
against cancer and intracellular parasites such as viruses. The 
processes by which cytolytic lymphocytes destroy such cells 
is not completely understood. Current concepts view cytol- 
ysis as a multistep physiologic process minimally involving 
initial weak attachment of the lymphocyte to the target cell, 
specific recognition, transmembrane signaling that strengthens 
attachment, further bidirectional signaling events that ulti- 
mately program the target cell for destruction, lysis of the 
target cell, and recycling of the effector cell to another target 
(for reviews see references 1-5). These processes  are likely medi- 
ated by receptor-ligand interactions that may vary somewhat 
depending on the particular combination of effector and target 
cell and/or the cytolytic pathway used (5,  6). 
Evidence for at least three separate lytic pathways has been 
demonstrated.  One  pathway  involves  exocytosis  of lytic 
granules into the cleft formed by the lymphocyte and the 
target cell membranes (4, 7, 8). Another pathway is effector 
cell-induced target cell autolysis,  i.e.,  apoptosis (9,  10). A 
third cytolytic pathway involves influx of ions and water 
into target cells leading to osmotic shock and cellular  dis- 
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been suggested to play an important role in this latter path- 
way (14). Incubation of tumor cells with ATP induced Ca  2  + 
mobilization,  plasma  membrane  depolarization,  activation 
of phospholipase C, osmotic swelling, and cell lysis (15-18), 
characteristics commonly observed in tumor cells during lym- 
phocyte-mediated cytolysis (11-13). It is significant that elevated 
levels of eATP are detected in the early phase of lymphocyte- 
mediated tumor cell death (19). The mechanisms by which 
eATP is generated and used during the cytolytic process have 
not been elucidated. 
During investigation of cytolytic lymphocyte-target cell 
interaction, we identified a number of lymphocyte-binding 
tumor plasma membrane proteins (20). Based on structural 
and immunologic properties, we now report that one of these 
tumor membrane proteins has homology to the 3  (catalytic) 
subunit  of H §  transporting  ATP  synthase  (E.C.3.6.1.34, 
3-H + ATPase) a molecule thought  to be exclusively located 
in mitochondria (21).  Functional assays  suggest  that 3-H + 
ATPase is involved in a cytolytic pathway that functions in 
naive NK  cells and  IL-2-activated killer (LAK) cells. 
Materials and Methods 
Chemicals and Antibodies.  N-hydroxy succinamide ester of bi- 
otin (biotin-NHS) was purchased from Calbiochem-Novabiochem 
Corp. (La Jolla, CA). Streptavidin-alkaline  phosphatase and all cell 
culture media and reagents were from GIBCO BILL (Gaithersburg, 
MD). Chemicals used for electrophoresis were purchased from Bio- 
Pad Laboratories (Melville,  NY). All other chemicals  used were 
obtained  from  Sigma  Chemical  Co.  (St.  Louis,  MO).  Mouse 
anti-rabbit IgG was purchased from Pierce (Rockford, IL). Goat 
anti-rabbit IgG conjugated to FITC was obtained from Tago, Inc. 
(Burlingarne,  CA).  Antibody against 3-H§  (anti-3) was 
kindly provided by Drs. P. J. Thomas and P. L. Pederson (Johns 
Hopkins University, Baltimore, MD). Anti-3 was raised in rabbits 
against a 21-met peptide corresponding to the amino acid sequence 
Y311 to A331  of ~-H+ATPase and had a titer of 1:50,000  (22). 
Cell Isolation and Culture.  Cell lines used in this study were ob- 
tained from the American Type Culture Collection (RockviUe, MD) 
and were maintained  in  media  according  to  their instructions. 
Human erythrocytes and human PBL (HPBL) were isolated as de- 
scribed previously (23,  24). Briefly, blood obtained from healthy 
volunteers was diluted 1:1 with HBSS, layered on Ficoll-Hypaque 
(Pharmacia, Piscataway, NJ), and centrifuged at 200 g for 20 min. 
The pelleted erythrocytes were washed three times with HBSS and 
used fresh.  HPBL were depleted of B cells and monocytes by pas- 
sage of the mononuclear leukocyte fraction (Ficoll-Hypaque inter- 
face layer) through nylon wool columns. LAK activity was gener- 
ated by incubation of freshly isolated  HPBL at 106 cells/ml with 
30 U  rIL-2/ml (R&D Systems,  Inc., Minneapolis, MN) for 6 d 
at 37~  in 5%  CO2 (23,  24). 
Purification of Tumor Membrane Proteins.  Approximately  109 
cells of erythroleukemia cell line (K562) were washed three times 
with 10 mM phosphate, pH 7.4, containing 145 mM NaC1 (PBS) 
1  Abbreviations used in this  paper: biotin-NHS, N-hydroxy succinamide ester 
of biotin; B-H+ATPase, /3 subunit of H + transporting ATP synthase; 
eATP, extracellular ATP; HPBL, human peripheral blood lymphocytes; 
p51.5, a 51.5-kD plasma membrane protein of a human erythroleukemia 
cell line (K562). 
and used to prepare plasma membranes as described previously (25). 
Plasma membrane proteins were solubilized with 1% Triton X-100 
overnight at 4~  in a buffer containing 10 mM sodium borate, 
10 mM benzamidine,  1 mM EDTA,  1 mM iodoacetamide, and 
I mM PMSF, pH 8.0 (buffer A). Protein concentrations were de- 
termined by the method of  Bradford (26). Solubilized proteins were 
extensively dialyzed against buffer A and subjected  to preparative 
SDS-PAGE (27). A vertical portion of the gel was sliced and stained 
with Coomassie blue to locate the desired protein. Protein bands 
of interest were cut from the gel, eluted, and further purified by 
SDS-PAGE. A portion of the purified protein was extensively dia- 
lyzed against  10 mM Tris-HC1, 0.1 mM EDTA, pH 8.0, and used 
either for cytotoxicity inhibition studies or labeled with biotin as 
described previously (25)  for study of its binding properties to 
HPBL. A  portion of the purified protein was  also  isolated  on 
nitrocellulose paper by SDS-PAGE and transblotting (27, 28) and 
utilized  for NH2-terminal  amino  acid  sequence  analysis  (Yale 
University Microsequencing Laboratory, New Haven, CT). 
Immunoprecipitation.  Plasma membrane proteins of viable tumor 
cells were first labeled with biotin according to standard techniques 
(29, 30). Briefly, cells (>99% viable by trypan blue dye exclusion) 
were washed three times with a solution containing 10 mM Hepes, 
145 mM NaC1, 4 mM KC1, 11 mM glucose,  pH 8.0, (buffer B), 
and then incubated in the same buffer with biotin-NHS (1 mM 
biotin-NHS/106 cells) for 1 h  at 4~  Subsequently,  cells were 
washed three times with 20 vol of buffer B to remove unreacted 
biotin, and plasma membrane proteins were prepared as described 
above. 
Anti-3 was incubated with mouse anti-rabbit IgG coupled to 
CNBr-Sepharose 4B at 4~  for 90 min in PBS containing 1%o BSA. 
The reacted beads  were washed three times with buffer and in- 
cubated at 4~  for 90 min with biotinylated tumor plasma mem- 
brane proteins. The beads were then washed three times with PBS 
containing 1% BSA and two times with PBS alone, suspended in 
Laemmli SDS-PAGE sample buffer, and boiled for 10 min. The su- 
pernatant was subjected to SDS-PAGE (27) and proteins from gels 
were transferred to Immobilon-P membrane (Millipore Corp., Bed- 
ford, MA) by electroblotting (28).  The immunoprecipitated bi- 
otinylated tumor membrane proteins were identified on blots by 
reaction with a streptavidin-biotin detection system (25). 
Binding of Tumor Plasma Membrane Proteins to  Viable LymFho- 
cytes.  Plasma membrane proteins of tumor cells or purified pro- 
teins were prepared as described above. Proteins were labeled with 
biotin and reacted with freshly isolated viable HPBL at a ratio of 
2:1 (on the basis ofceU numbers) in RPMI-1640 supplemented with 
15% FCS at 4~  for 2 h. The coated HPBL were washed twice 
with media and three times with buffer B. Finally, cells were solu- 
bilized in Laemmli sample buffer and the solubilized proteins were 
subjected to SDS-PAGE and Western blotting. Biotinylated tumor 
membrane proteins that bound to lymphocytes were identified with 
a streptavidin-biotin detection system  (25). 
Fluorescence-activated Flow Cytometry.  Approximately 106 cells 
were washed three times with PBS containing 0.1% BSA (PBS- 
BSA) and incubated with appropriately diluted anti-3 at 4~  for 
30 rain. Cells were then washed three times with PBS-BSA and 
reacted with  FITC-F(ab')2 goat anti-rabbit  IgG for 30 rain  at 
4~  Finally,  cells  were  washed  three  times  with  PBS-BSA, 
resuspended to a concentration of 106 cell/ml (viability >  95%), 
and analyzed on a cytofluorograph, model IIs (Ortho Pharmaceu- 
tical,  Raritan,  NJ). 
Lymphocyte-mediated Cytotoxicity.  Cytolysis of tumor cells by 
HPBL was measured as described previously (23, 24). In brief, 100 
/A of SlCr-labeled target cells (2  x  104 cells/ml) was mixed with 
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tions of E/T cell ratios of 100:1 to 6:1. Cells were incubated at 
37~  for 3 h in 5% CO2. Incubation of target cells without the 
effector cells and in media alone served as control for spontaneous 
release of 5~Cr, and wells without effector cells but with 1% SDS 
provided the maximum amount of radioactivity present. Cytolysis 
was  calculated as  percent  cytotoxicity  =  100  x  [(cpm~xp - 
cpm,po,t)/(cpmm~x -  cpm,pont)]. 
R.esu]ts 
Binding  of  Tumor  Plasma  Membrane  Protein p51.5  to 
HPBL.  To identify tumor membrane proteins that bind to 
lymphocytes, we adopted a technique that was successfully 
utilized to characterize receptor-ligand interactions between 
Staphylococcus  aureus and human endothelial cell plasma mem- 
brane proteins (25).  Initial studies were performed with the 
NK-sensitive K562  tumor cell line.  Solubilized membrane 
proteins from surface biotin-labeled K562 cells were reacted 
with freshly isolated HPBL.  Western blots of these solubi- 
lized HPBL preparations revealed a number of lymphocyte- 
binding tumor membrane proteins (Fig.  1, lane A). Protein 
of one of the major bands (molecular mass 51-55 kD) was 
purified by preparative gel electrophoresis from K562 mem- 
brane extracts for further study. The purified K562 protein 
appeared as a single band of 51.5-kD molecular mass (p51.5) 
upon SDS-PAGE  (Fig.  1, lane B). The binding property of 
purified p51.5  was examined by an identical protocol used 
to identify lymphocyte-binding tumor proteins from crude 
membrane preparations. Representative experiments demon- 
strated that purified p51.5  retained its lymphocyte-binding 
property (Fig.  1,  lane C). 
Effect of  Purified  p51.5 on NK Cell-mediated Cytolysis.  Since 
p51.5 from the prototypical NK target cell bound to the plasma 
membrane of HPBL,  we hypothesized that it might func- 
tion as a ligand in the cytolytic process.  To test this proposal, 
a NK cytotoxicity assay system was utilized where freshly 
isolated HPBL were cultured with purified p51.5 before and 
during incubation with StCr-labeled  K562 target cells. We 
Figure  1.  Binding of K562 mem- 
brane proteins to HPBL. (Lane A) A 
representative blot of surface-labeled 
K562 membrane proteins  that bind 
to HPBL. K562 membrane proteins 
from surface biotinylated  cells were 
reacted with freshly isolated viable 
HPBL.  The  treated  HPBL  were 
washed  with buffer,  solubilized in 
Laemmli sample buffer, and proteins 
resolved by SDS-PAGE. Biotinylated 
tumor plasma  membrane proteins that 
bound to  HPBL  were  detected  on 
Western  blots  by  a  standard 
streptavidin-alkaline phosphatase de- 
tection system. (Lane B) A Western 
blot of Coomassie blue-stained purified p51.5 K562 membrane protein. 
(Lane C) A Western blot of a HPBL extract derived from viable HPBL 
that were reacted with purified biotin-labeled p51.5. The binding  reaction 
was performed with purified p51.5 by the same method as used for lane 
A  experiments. 
reasoned that under these experimental conditions the ligand 
binding  site of the putative p51.5  NK receptor would be 
blocked by soluble p51.5, thereby preventing engagement of 
the "physiologic" ligand on K562 cells.  Indeed, significant 
inhibition in NK-mediated cytolytic activity was observed 
when p51.5-treated HPBL were used as effector cells com- 
pared with untreated lymphocytes (Fig.  2).  The extent of 
inhibition was dependent on the concentration of purified 
p51.5  reacted with the HPBL. An 80-kD K562 membrane 
protein (which did not bind to HPBL) was purified and studied 
for its ability to block NK activity in an identical manner 
to p51.5.  As shown in Fig. 2 the 80-kD membrane protein 
was unable to block NK-mediated cytotoxicity. 
Structural Characterization ofF51.5.  To investigate the iden- 
tity of p51.5,  NH2-terminal amino acid sequence analysis 
was performed on SDS-PAGE-purified protein as described 
above. Of the first 21 cycles, a single amino acid was identified 
at each of 16 positions with a high degree of  confidence (Table 
1). This sequence was compared with known sequences in 
GenBank (see Table  1). The search revealed 100%  identity 
at each of these positions with residues at the NH2-terminus 
of the ~  subunit of/$-H +  ATPase, a molecule that is part of 
a multimeric mitochondrial enzyme complex (21).  A com- 
parison of quantitative data from the sequenced amino acids 
and from total protein amino acid analysis suggested that the 
sequence was derived from the major species in the prepara- 
tion which account for >95%  of the total protein. 
The origin of/$-H +  ATPase in the crude membrane prepa- 
rations used in the above studies could be ascribed solely to 
contamination of these extracts with mitochondria. This pro- 
posal, however, does not explain the observations that surface- 
labeled p51.5  bound  to  HPBL  (Fig.  1)  and inhibited NK 
cell-mediated cytotoxicity  in contrast to another tumor mem- 
brane protein (Fig.  2). These latter data strongly suggested 
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Figure 2.  Effect  of purified K562 membrane proteins on NK cell-medi- 
ated cytotoxicity. HPBL were first incubated with the indicated amount 
of purified proteins (40 ng/~l based on amino acid analysis) at 37~  for 
30 min and then added to 51Cr-labeled  1(562 cells at an E/T ratio of 100:1. 
Percent cytotoxicity was determined  after 3-h incubation by the release 
of stCr and the data expressed as percent inhibition relative to a buffer 
control. Percent cytotoxicity against K562 cells  with buffer alone was 55%. 
(O-O) p51.5 and (A-A) p80 K562 membrane proteins. Representative 
data of three  experiments is shown. 
275  Das et al. Table  1.  NHrterminal Amino Acid Sequence of p51.5 K562 
Membrane Protein: Comparison with the Known  Sequence of 
Human fl-H +  ATPase 
1  10  20 
51.5-kD-K562 
Membrane  protein 
(p51.5) 
3-H+ATPase 
(EC 3.6.1.34) 
XXQTXPXPKAGXATGXIVAVl 
AAQTSPSPKAGAATGRIVAVI 
Amino acid sequence  analysis  was performed on p51.5 purified  by prepara- 
tive SDS-PAGE as described in Materials and Methods. Amino acid at 
position X could not be identified with high certainty. The sequence  of 
the p51.5 peptide was compared to B-H§  by GenBank, Sequence 
Analysis Software  Package, Genetics  Computer  Group (University  Research 
Park, Madison WI). 
that  a 3-H+ATPase-like  molecule is expressed on the  sur- 
face of tumor cells. Accordingly, immunologic studies were 
conducted  to  establish whether  a 3-H+ATPase-like  mole- 
cule (p51.5) is expressed on the exterior of tumor cell plasma 
membranes.  Additionally, immunologic characterization  of 
the  molecule that  bound  to  HPBL was performed. 
Immunologic  Characterization  of K562  Plasma  Membrane 
p51.5.  Affinity-purified antibody directed against a peptide 
in  the  ATP-binding  region  of 3-H+ATPase  (anti-3,  see 
Materials and Methods) was used to study the expression of 
3-H+ATPase  on  the  plasma  membrane  of representative 
tumor cell lines  and  normal  ceils by fluorescence-activated 
flow cytometry and immunoprecipitation.  Viable cells were 
reacted  with  anti-3,  and  then  reacted  with  FITC-F(ab')2 
goat anti-rabbit IgG. Under these conditions, anti-3 bound 
to  ,090%  of K562  cells but  did not  bind  substantially  to 
HPBL or human erythrocytes (Fig. 3). Flow cytometry anal- 
ysis of a human  lung adenocarcinoma cell line (A549)  and 
a Burkitts lymphoma cell line (Raji) also demonstrated >90% 
reactivity with anti-3  (data not shown).  These results sug- 
gest the presence of a molecule on the surface of a variety 
of tumor cell lines (but not normal human lymphocytes and 
erythrocytes) that has immunologic identity or cross-reactivity 
to 3-H +ATPase. 
Western blots of K562 extracts were probed to determine 
the number of proteins that  might  cross-react with anti-3. 
It is significant that anti-3 reacted with only a single protein 
band of 51.5  kD on the Western blots of whole K562 cell 
extracts as well as extracts of K562 plasma membrane (Fig. 
4). Identical results were obtained with A549, Raji, and HPBL. 
Serum from nonimmune rabbits or rabbits immunized against 
an irrelevant protein lacked reactivity against p51.5 (data not 
shown). These findings strongly suggest that anti-3 does not 
react  with  cellular proteins  other  than  3-H +ATPase. 
To directly demonstrate  that  the  Y311  to A331  epitope 
of 3-H +  ATPase is expressed by a 51.5-kD tumor protein of 
plasma membrane origin, solubilized membrane protein from 
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Figure  3.  Flow  cytometry  analysis 
of anti-B-treated cells. Lymphocytes 
and K562  cells  treated  with secondary 
antibody alone (i.e., goat anti-rabbit 
F(ab')2 IgG-FITC) were <5% posi- 
tive. Data are representative of three 
experiments. 
surface biotin-labded K562 cells or control HPBL were reacted 
with anti-3.  (Antibody directed against  the above epitope, 
which constitutes a portion of the ATP-binding domain, is 
important  for the catalytic function of 3-H +ATPase; 22). A 
single biotinylated protein  of 51.5  kD was detected in the 
immunoprecipitate  of  the  K562  membrane  preparation, 
whereas the immunoprecipitate  from HPBL did not reveal 
biotinylated protein from the cell surface (Fig. 5, lanes A and 
B, respectively).  Immunoprecipitation studies with anti-3 also 
demonstrated plasma membrane--reactive protein (51-55 kD) 
on  A549  and  Raji  cell  lines  (Das,  B.,  unpublished  data). 
Western blot analysis of the above anti-/3-reacted membrane 
extracts with an anti-3 probe revealed the 51.5-kD band in 
HPBL as well as tumor cell preparations.  This experiment 
demonstrates that B-H +  ATPase can be immunoprecipitated 
from HPBL membrane  preparations  but  the origin  of the 
reactive material must be from the interior of the cell (i.e., 
mitochondrial)  since it is not labeled with biotin  (compare 
lanes B  and D  of Fig.  5). 
Characterization of  the 51.5-kD Lymphocyte-binding Protein.  It 
Figure  4.  Reactivity  of anti-3 with K562 
proteins. Proteins from whole cell (lane A) 
or crude membranes (lane  B) were  separated 
by SDS-PAGE  and transblotted. Blots were 
reacted  with  anti-3  followed by  goat 
anti-rabbit-alkaline phosphatase and devel- 
oped  by reaction with Nitroblue  Tetrazolium 
chloride and 5-Bromo-4 Chloro-3-indolyl- 
phosphate p-Toluidine (25). 
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immunoprecipitates  from surface- 
labeled cells. (Lanes A  and B) 
Western  blots of anti-B  immuno- 
precipitated  proteins from surface 
biotinylated  K562 cells and lym- 
phocytes,  respectively.  Proteins  in 
these lanes were probed with 
streptavidin-alkaline  phosphatase 
for the detection  of anti-B-reac- 
tive biotinylated plasma mem- 
brane proteins. Note that only 
K562 cells are positive  indicating 
the presence of a B-H+ATPase-like protein on the surface of K562 
cells but not tymphocytes.  (Lanes  C and D) Western  blots of  the same anti-B 
immunopredpitated  membrane  proteins (lanes  A and B) that were  probed 
with anti-B, and developed  with goat anti-rabbit alkaline phosphatase. 
Bands represent  both ceU surface  as well  as internal  anti-B-reactive  proteins. 
is conceivable  that a contaminating protein  (<5%)  in the 
51.5-kD isolate (used for amino acid sequence  analysis and 
adhesion studies) is in fact the lymphocyte-binding  molecule 
rather than/3-H+ATPase. We, therefore, directly investigated 
whether the lymphocyte binding protein of 51.5 kD from 
the plasma membranes of K562 tumor cells reacts with anti-~. 
Freshly isolated viable HPBL were first reacted with plasma 
membrane proteins from cell surface-labeled  K562 cells. Sub- 
sequently, HPBL were washed to remove unbound tumor 
proteins and then the HPBL were lysed and the proteins solu- 
bilized. The extract from the treated HPBL was reacted with 
anti-~,  and  the resulting immunoprecipitate subjected to 
SDS-PAGE, Western blotting, and analyzed for biotin-labeled 
proteins. The Western blot of this experiment revealed a single 
biotinylated K562 membrane protein of 51.5 kD indicating 
that this lymphocyte-binding  protein contains the Y311-A331 
epitope of B-H+ATPase (Fig.  6  left). 
Anti-~ reacts with a peptide sequence of B-H+ATP that 
is involved in the binding of ATP (22). Presumably this anti- 
body would not react with/~-H +  ATPase if the ATP-binding 
site was occupied, e.g., by combining with a receptor on lym- 
phocytes. To examine this possibility, HPBL were either in- 
cubated with purified p51.5 or with medium alone, washed, 
and then reacted with anti-/3.  These two preparations were 
further treated with FITC-F(ab')2 goat anti-rabbit IgG and 
analyzed by fluorescence-activated  flow cytometry. Anti-~ 
bound to only those lymphocytes that were first reacted with 
p51.5 (Fig. 6 right), suggesting that the ATP-binding site of 
this ligand is not occupied upon reaction with HPBL. 
Effect of Anti-fl  on  the Lymphocyte-mediated  Cytolytic  Ac- 
tivity.  The effect of anti-~ on cytolytic  activity of naive NK 
and LAK cells was determined. 5tCr-labeled K562 and A549 
cells (NK-sensitive target cells and NK-resistant LAK-sensitive 
target cells, respectively)  were first reacted with anti-/3 and 
then incubated with effector ceils. Significant inhibition in 
NK-mediated cytolytic  activity of naive HPBL as well as LAK 
cytotoxicity  was observed with anti-/3-treated  target cells (Fig. 
7,  A  and B).  Inhibition in cytolytic activity was directly 
proportional  to  the  concentration of anti-/3  used  at  two 
different E/T ratios. Inhibition was nearly 100% for NK ac- 
tivity at the lowest E/T cell ratio and highest concentration 
Figure  6.  (Left)  Western  blot of the anti-B  immunoprecipitate  of the 
extract of HPBL that were previously  reacted with membrane  proteins 
of the surface  biotinylated  K562 cells. Briefly,  HPBL  were reacted  with 
membrane  proteins  from  surface  biotinylated  K562 cells,  washed, and solu- 
bilized in 1% Triton  X-100. Solubilized  proteins from these HPBL  were 
immunoprecipitated  with anti-B as described  in Materials  and Methods. 
Immunoprecipitated proteins were separated by SDS-PAGE and HPBI_, 
bound K562 biotinylated  plasma membrane  anti-B-reactive  protein was 
detected on Western  blot by reaction  with streptavidin-alkaline  phospha- 
tase as described  for Fig. 5, lanes  A and  B. (Right) Flow  cytometry  analysis 
of p51.5-treated lymphocytes:  interaction  with anti-B. HPBL  (2.5 ￿  106 
cells) were  first  incubated  with 13 (Q-S) or 50 #g (  ) ofp51.5, washed 
with buffer  A, incubated  with 1:1,000 diluted  anti-B (4~  30 min), and 
analyzed  by flow  cytometry.  HPBL  without p51.5 treatment  (.....) served 
as a control. The mean  channel  shift (MCS) of fluorescence  intensity  of 
HPBL treated  with 13 and 50 #g p51.5 was 13 and 144, respectively,  as 
compared with the untreated cells. MCS of >10 is considered positive. 
Representative results from two studies are shown. 
of anti-/~ (1:20 dilution). Under similar conditions, LAK cell 
activity  was inhibited by 75%. Undiluted normal rabbit serum 
and undiluted IgG fraction of rabbit anti-BSA had no effect 
on NK cell cytotoxicity. 
Discussion 
Structural and immunologic investigations demonstrate for 
the first time a 51.5-kD protein (p51.5) on the plasma mem- 
brane of several human tumor cell lines that has homology 
to B-H +  ATPase. This protein was not detected on the sur- 
face of normal lymphocytes and erythrocytes. Binding and 
functional studies suggest that p51.5 serves as a ligand in the 
effector rather than the recognition phase of MHC-indepen- 
dent, cell-mediated cytotoxicity. 
~-H+ATPase is  thought to  function exclusively  as  the 
catalytic subunit of the mitochondrial enzyme responsible 
for ATP synthesis (21). It was therefore unexpected to obtain 
data  suggesting  the  expression  of  B-H+ATPase  on  the 
plasma membrane of tumor cells. The present study cannot 
rule out the unlikely possibility of two distinct proteins, one, 
mitochondrial B-H +  ATPase and the other, a tumor plasma 
membrane/3-H+ATPase-like molecule, both characterized 
by the same apparent molecular weight (51.5 kD), structural 
identity at the NH2-terminus, and sharing the Y311 to A331 
epitope but differing in other regions of the molecule. NHz- 
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Figure 7.  Effect of anti-3 treatment of tumor cells on NK- and LAK-mediated cytotoxicity, slCr-labeled target cells were incubated at 4~  for 
30 min with different dilutions of anti-3 before the addition of fresh unstimulated HPBL (naive NK cells) or IL-2-activated  HPBL (LAK cells). Percent 
cytotoxicity was determined after 3-h incubation by slCr release, and data expressed as percent inhibition relative to a buffer control. (A) Effect of 
anti-3 treatment of K562 cells on NK cell-mediated cytotoxicity. (O-O) E/T ratio of 25:1 and (A-A) E/T ratio of 50:1. Cytotoxicity of HPBL 
against K562 cells without anti-3 (buffer control) was 30% (E/T 25:1) and 59% (E/T 50:1). (B) Effect of anti-3 treatment of A549 cells on LAK 
cell-mediated cytotoxicity. (O-I) E/T of 25:1 and (A-A) E/T of 100:1. Cytotoxicity  of LAK cells against A549 cells without anti-3 (buffer  control) 
was 14% (E/T 25:1) and 35% (E/T 100:1). Fresh unstimulated HPBL had no detectable  cytolytic  activity against A549 cells (NK-resistant tumor). 
Incubation of slCr-labeled K562 and A549 cells with anti-3 alone had no observable  effect  on cell viability. Data are representative of two experiments. 
terminal  amino  acid  sequence  analysis  of p51.5  indicated 
100% homology  (at  16  of the  21  positions  identified)  to 
3-H+ATPase. SDS-PAGE-purified p51.5 contained a single 
species of protein as deduced by combined quantitative amino 
acid analysis  of the total protein and the NH2-terminal  se- 
quenced amino acids.  Whereas it is likely that a significant 
amount ofp51.5 was derived from mitochondria (which con- 
taminate crude plasma membrane preparations), immunologic 
studies clearly revealed that  the protein was also expressed 
on the cell surface.  Antibody generated against a peptide in 
the  ATP-binding  region  of 3-H+ATPase  (anti-3)  reacted 
with viable tumor cells as determined by fluorescence-activated 
flow cytometry. Since the antibody reacted only with a single 
protein of 51.5  kD on Western blots of solubilized mem- 
brane or whole cell extracts, it is exceedingly unlikely that 
the immunofluorescence data could be accounted for by cross- 
reactivity of anti-3 with other nucleotide-binding proteins. 
Furthermore, immunoprecipitation  studies of surface-labeled 
cells utilizing anti-3 indicated immunologic reactivity with 
a single 51.5-kD protein on the plasma membrane of tumor 
cells.  Taken together,  the above studies suggest that plasma 
membrane-bound p51.5 and mitochondrial-derived p51.5 are 
identical  or nearly so. 
It  is  conceivable  that  intracellular  proteins  (e.g.,  3- 
H+ATPase) may be released from a small percentage of dead 
tumor cells in tissue culture and that the protein may bind 
to the surface of the remaining  viable cells.  The latter pro- 
posal cannot, however, explain the substantial amount of anti- 
3-reactive protein detected on the plasma membrane of tumor 
cells relative to normal cells. Comparison of surface-labeled 
p51.5 to whole cell extract-labeled p51.5 by semi-quantitative 
ELISA analysis indicated that "~40% of the total cellular anti- 
3-reactive protein in K562 cells  is associated with  the ex- 
terior of the plasma membrane (Das, B., unpublished data). 
Since only 1% of the tumor cells was nonviable, it is doubtful 
that  they could contribute  the amount  of surface p51.5  as 
determined in the above estimates.  Moreover, immunopre- 
cipitation studies of surface-labeled tumor cells indicate that 
p51.5 could not be removed from the membranes by treat- 
ment with 0.5 M  NaC1 and/or 1 mM EDTA (Das, B., un- 
published data). These results further rule out the possibility 
that 3-H+ATPase is bound to the cell surface by nonspecific 
interaction,  i.e.,  binding  of p51.5 from dead cells.  Further 
studies are in progress to establish the mode of attachment 
of p51.5  to  the plasma membrane. 
Data presented in this report demonstrate that cell surface 
3-H+ATPase or a molecule that is remarkably similar acts 
as a functional ligand in lymphocyte-mediated cytotoxicity. 
Purified p51.5, in contrast to another tumor membrane pro- 
tein,  bound  to  human  lymphocytes,  suggesting  a  specific 
receptor-ligand  interaction.  Labeled p51.5 from surface bi- 
otinylated  K562  cells  could be immunoprecipitated  from 
HPBL treated with crude tumor membrane extracts by specific 
antibody to 3-H +  ATPase. p51.5-treated HPBL were blocked 
in their ability to mediate NK cytotoxicity presumably be- 
cause of inability of the lymphocyte receptor to engage the 
p51.5 ligand on the plasma membrane of K562 target cells. 
Furthermore, anti-3 was exceedingly effective in blocking naive 
NK cytotoxicity (>95% inhibition) and highly effective (75% 
inhibition) in preventing LAK cytotoxicity. We note that the 
antibody used in the latter studies was whole IgG. It is well 
known that NK cells can mediate lysis of NK-resistant target 
cells if IgG is specifically bound to the cell surface (antibody- 
dependent, cell-mediated cytotoxicity, ADCC) (3, 6). Con- 
sequently, one may infer that the ADCC pathway uses p51.5 
as a ligand  since inhibition  of cytotoxicity, rather  than  en- 
hancement, was observed with the anti-3 treatment ofK562 
and A549 cells.  These data are consistent with the hypoth- 
esis that 3-H +ATPase serves as a ligand in the effector rather 
than the recognition phase of a common final lytic pathway 
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tion is likely due to different molecular species in cells medi- 
ating the latter activities. 
It is interesting to note that anti-3 was relatively ineffec- 
tive in blocking cytotoxicity mediated by the YT cell line 
(<25% inhibition). Since YT-induced tumor destruction is 
mediated to a large extent by lytic granules (31), p51.5 is prob- 
ably not utilized as a ligand in the granule exocytosis pathway. 
In this regard, Yaliante and Trinchieri (32)  have identified 
a signal transduction surface molecule on cytolytic lympho- 
cytes that does not mediate release  of granule enzymes. 
Experimental evidence suggested that the ATP-binding do- 
main and the lymphocyte-receptor binding site of p51.5 are 
located in different regions of the molecule. Flow cytometry 
analysis indicated that antibody directed against an epitope 
in the ATP-binding domain (anti-/~) of 3-H +  ATPase could 
react with the solubilized p51.5 which was bound to the sur- 
face of lymphocytes. This finding suggests that the catalytic 
site of p51.5 was not blocked upon interaction of the mole- 
cule with its lymphocyte receptor. We infer that inhibition 
of cytotoxicity by anti-3 is not due to blockage of receptor- 
ligand engagement but rather is due to inhibition of the cata- 
lytic function of the ligand. Of course, it is possible that p51.5 
may function in cytotoxicity in a different manner from its 
usual catalytic role. Indeed the ot subunit of the mitochon- 
drial  H+-transporting  ATP  synthase  has  been  found  in 
peroxisomes and was suggested to function as a molecular 
chaperon in both organeUes,  besides its usual role in ATP 
synthesis in mitochondria (33). 
Mitochondrial H + transporting ATP synthase is a multi- 
meric enzyme that is composed of two functional domains; 
"F0,"  the transmembrane H + channel, and "FI"'  the cata- 
lytic site for ATP synthesis (21, 34). The 3 subunit that con- 
tains the ATP-binding domain (catalytic site) of the enzyme 
is a protein encoded by a nuclear gene. In normal ceils it is 
synthesized in the cytoplasm and translocated to the inner 
membrane of mitochondria where it associates as a nontrans- 
membrane protein with other subunits of the F1 complex 
(21, 34-36). Whereas altered expression of such a molecule 
on tumor cells was unexpected, previous studies (37-40) have 
shown a decrease in ATP synthase activity and a reduction 
in the content of F1 components in mitochondria isolated 
from neoplastic cells and from cells of regenerating tissues. 
Significant  alterations in the content of F0 were not observed 
in these studies (38--40).  Postulated causes of alterations in 
the F1 complex of cancer cells were decreased synthesis of 
F1 proteins, defective mitochondrial uptake of the proteins, 
and/or abnormal translocation of F1 subunits (38-40). Data 
in this report support the latter hypothesis. Clearly, further 
studies are necessary to determine if p51.5 expression on the 
plasma membrane occurs in a wider variety of tumors and 
normal tissues compared with the limited number examined 
in the present investigation. 
The interaction of plasma membrane 3-H +  ATPase with 
a putative lymphocyte receptor may provide insights into 
previous observations regarding the role of ATP in tumor 
cell destruction. Addition of ATP to culture of tumor cell 
lines is known to induce membrane depolarization, changes 
in permeability, and eventual lysis of a variety of transformed 
cells (14-18, 41, 42). Nontransformed cells, with the excep- 
tion of mast cells (43) and macrophages (44), were unaffected 
by exogenous ATP. The cytolytic effect of ATP on these cells 
was specific in that other purine or pyrimidine nudeotides 
did not mimic the response. Rozengurt et al. (15,  16) sug- 
gested that ATP facilitates  the formation of aqueous ionic 
pores resulting in imbalance in ionic homeostasis, swelling, 
and eventual lysis of cells. 
Based on the above observations, these investigators sug- 
gested that lymphocyte-induced tumor destruction may use 
eATP as a mediator in a lytic pathway (14, 41, 42). Direct 
evidence for this proposal, although quite limited, is neverthe- 
less compelling. Henney (19),  while investigating possible 
markers of lymphocyte-induced target cell death, observed 
an increase in eATP within minutes of effector-tumor cell 
interaction.  The  amount  of ATP  in  the  supernatant  was 
significantly greater than the amount present in target cells 
alone. Although contribution of ATP from effector cells due 
to leakiness was suggested, lymphocyte permeability altera- 
tions using other markers were not observed (19). Filippini 
et al.  (45)  demonstrated an increase in lymphocyte plasma 
membrane-associated ATP after stimulation of T cells by anti- 
CD3 antibody or by Con A. The latter investigators sug- 
gested that ATP may be generated at the cell surface of the 
lymphocyte upon activation by the target cell.  Our results 
demonstrating the presence of 3-H+ATPase on the surface 
of neoplastic cells, and the inhibitory effect of both soluble 
p51.5 and anti-3 suggest the involvement of an energy-using 
system of tumor membrane origin in lymphocyte-mediated 
cytotoxicity since the/~ subunit can in fact, under appro- 
priate conditions, hydrolyze ATP to ADP (46-48). Whereas 
the precise mechanism by which 3-H+ATPase functions in 
lymphocyte-mediated  cytotoxicity remains to be determined, 
it is tempting to speculate that p51.5, upon combination with 
its lymphocyte receptor(s), may provide energy for transport 
of H +  across  the plasma membrane into  the  tumor  cell 
resulting in cytolysis by osmotic shock. Target cell membrane 
depolarization and osmotic swelling are well-known phe- 
nomena in lymphocyte-mediated destruction of tumors (11, 
13). The orientation of 3-H+ATPase on the plasma mem- 
brane with its extraceUular ATP binding domain would permit 
such activity. 
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